AIM ImmunoTech Inc. (AIM)
- Previous Close
0.4757 - Open
0.4900 - Bid 0.4000 x 800
- Ask 0.5337 x 800
- Day's Range
0.4500 - 0.4999 - 52 Week Range
0.3200 - 0.7500 - Volume
176,541 - Avg. Volume
234,143 - Market Cap (intraday)
23.798M - Beta (5Y Monthly) -0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
aimimmuno.comRecent News: AIM
Performance Overview: AIM
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AIM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AIM
Valuation Measures
Market Cap
23.80M
Enterprise Value
12.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
114.70
Price/Book (mrq)
2.49
Enterprise Value/Revenue
60.07
Enterprise Value/EBITDA
-0.38
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-66.64%
Return on Equity (ttm)
-118.94%
Revenue (ttm)
202k
Net Income Avi to Common (ttm)
-28.96M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
13.07M
Total Debt/Equity (mrq)
7.02%
Levered Free Cash Flow (ttm)
-12.16M